Management of Autoimmune Hemolytic Anemia in the Midst of Coronavirus Disease 2019 Pandemic: A Case Report

Andree Kurniawan, Devina Adella Halim


Introduction : The novel coronavirus disease 2019 (COVID-19) has become a pandemic involving all people and can be severe and life-threatening in a certain population such as those with comorbidity. Autoimmune hemolytic anemia (AIHA) is an autoimmune hematologic disease characterized with antibodies production that binds to red cell surface antigens. In this pandemic, several concerns have been raised by autoimmune disease clinicians and patients regarding the use of immunosuppressive drugs. In this case report, we illustrate the problems of autoimmune hemolytic anemia patient when she got active case.

Case Illustration : A 28 years old lady was admitted to the hospital owing to fatigue and tiredness during exercise for two weeks. She had been diagnosed with autoimmune hemolytic anemia before and did not comply with the treatment. This patient has been reevaluated of having AIHA from the symptoms of fatigue, enlarged spleen, low hemoglobin, increased reticulocytes, signs of hemolytic in blood smear examination, increased indirect bilirubin, LDH and the Combs’ test result was given positive. She received methylprednisolone 2 mg/kg of body weight intravenously, washed packed red cells (PRC), calcium and proton pump inhibitor. She was discharged at the seventh day since admission and she was prescribed oral methylprednisolone equal to 1 mg/kg body weight.

Conclusion : This is an educated case of non-compliance of AIHA that should be given high dose steroid and blood transfusion during hospitalization amid the COVID-19 pandemic. The recommendation of treatment for AIHA was still the same as before the pandemic occured.


Autoimmune Hemolytic Anemia; AIHA ; Covid-19;


Full Text:



1. Worldometers. Coronavirus Disease 2019 [Internet]. [Update 2020 May 14th, cited 2020 May 15th]. Available from:

2. Zhou E, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-62. Epub 2020 Mar 11.

3. Chaudhary RK, Das SS. Autoimmune hemolytic anemia: from lab to bedside. Asian J Transfus Sci. 2014 Jan-Jun;8(1):5-12. PMCID: 3943148. PMID: 24678166.

4. Contentti EC, Correa J. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge. Mult Scler Relat Disord. 2020 Jun;41:102097. PMCID: PMC7131249. PMID: 32278860.

5. Fan BE, Ong KH, Chan SSW, Young BE, Chong VCL, Chen SPC, et al. Blood and blood product use during COVID-19 infection. Am J Hematol. 2020 Apr 12. [Epub ahead of print]. PMID: 32279352.

6. Barcellini W, Fattizzo B. Clinical implications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Disease markers. 2015.

7. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood 2017 June 129(22):2971-9.

8. American Society of Hematology COVID-resources. COVID-19 and ITP: Frequently asked questions. [version 2.0; last updated April 24, 2020; cited on May 15th 2020]. Available from:

9. World Health Organization. Coronavirus disease (COVID-19) advice for the public. [cited May 17th, 2020]. Available from:


  • There are currently no refbacks.

Copyright (c) 2020 Andree Kurniawan, Devina Adella Halim

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

favicon Fakultas Kedokteran | Universitas Pelita Harapan | Lippo Karawaci, Tangerang, Indonesia, 15811